Please assess the completion status of the following clinical trial:

Trial Title: Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Salmon and Durie criteria for initial diagnosis of multiple myeloma; transplant will be offered to patients with stage II or III multiple myeloma (MM) at diagnosis or have received chemotherapy and/or radiation therapy for progressive MM after initial diagnosis of stage I disease~* The patient must have the capacity to give informed consent~* Have received at least 4 cycles of conventional dose chemotherapy for MM~* DONOR: HLA genotypically identical sibling~* DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis for both peripheral blood stem cell (PBSC) allograft and subsequent DLI~* DONOR: Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian)~* DONOR: Age \< 75, older donors may be considered after consultation by Psychological Consultation Center (PCC)~Exclusion Criteria:~* Karnofsky score less than 60, unless due solely to myeloma~* Left ventricular ejection fraction less than 40%~* Bilirubin greater than 2 X the upper limit of normal~* Serum glutamic pyruvic transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) \> 2 X the upper limit of normal~* Diffusion lung capacity of carbon monoxide (DLCO) \< 50% (corrected) or receiving continuous supplemental oxygen~* Patients with poorly controlled hypertension~* Pregnancy~* Seropositive for the human immunodeficiency virus~* Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment~* Creatinine clearance \< 40 cc/min at the time of initial autografting evaluation~* Prior autograft (can be treated on alternative protocol)~* DONOR: Identical twin~* DONOR: Age less than 12 years~* DONOR: Pregnancy~* DONOR: Infection with human immunodeficiency virus (HIV)~* DONOR: Inability to achieve adequate venous access~* DONOR: Known allergy to G-CSF~* DONOR: Current serious systemic illness~* DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) criteria for stem cell donation as described in the standard practice guidelines of the institution

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Melphalan and PBSCT before TBI and Donor PBSCT) (Type: EXPERIMENTAL): CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete